Thelansis’s "Muscle-Invasive Bladder Cancer (MIBC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Muscle-Invasive Bladder Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Muscle-invasive bladder cancer (MIBC) is an aggressive malignancy characterized by the infiltration of urothelial carcinoma into the detrusor muscle layer of the bladder wall, carrying a high risk of systemic micrometastasis. Clinically, patients most frequently present with painless gross hematuria, irritative voiding symptoms, or pelvic pain. Diagnosis is established via transurethral resection of bladder tumor (TURBT) to confirm muscular invasion, with staging completed through CT or MRI of the abdomen and pelvis alongside chest imaging to rule out distant metastases. Molecularly, MIBC is heterogeneous, categorized primarily into basal-like and luminal-like subtypes that exhibit distinct clinical behaviors and therapeutic sensitivities. The definitive treatment standard for localized disease is neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy with bilateral pelvic lymphadenectomy. For patients ineligible for cisplatin, or those with residual disease post-surgery, adjuvant immunotherapy with nivolumab is standard. Alternatively, bladder-preserving trimodality therapy combining maximal TURBT with concurrent chemoradiation serves as a highly effective option for selected candidates. For metastatic or locally advanced disease, frontline management utilizes the combination of the antibody-drug conjugate enfortumab vedotin with the PD-1 inhibitor pembrolizumab, a regimen that has revolutionized survival outcomes over historical platinum doublets.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Muscle-Invasive Bladder Cancer (MIBC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report
Our team will get in touch with you shortly about the Muscle-Invasive Bladder Cancer (MIBC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report.